Bora Pharmaceuticals manufactures and packages clinical trial drug products for JAQBO tablets as Onconic prepares for U.S. Phase 3 trials for gastroesophageal reflux disease (GERD).
Bora Pharmaceuticals re-elected its Board of Directors, including 4 independent directors and 2 female members, reinforcing governance independence and diversity.
Bora Pharmaceuticals was founded in 2007 by Bobby Sheng, Chairman of Bora Group and CEO of Bora Pharmaceuticals, to build a CDMO. With over 25 years of biotech and healthcare experience, Sheng led Bora to become Taiwan’s top CDMO by manufacturing.
Founded in 2007, Bora Pharmaceuticals operates as a pharmaceutical services provider under a “Dual Engine” model, combining CDMO and commercial expertise to support product development and launches for partners.
The Internal Audit department, independent under the Board of Directors, reviews internal controls across all units, operations, and subsidiaries to ensure effectiveness.
Bora connects formulation development, clinical and commercial manufacturing, and packaging to deliver treatments and quality services to the healthcare and wellness industries globally.
Bora Pharmaceuticals prioritizes quality, reliability, and efficiency across the pharmaceutical supply chain, from research and development to sales and distribution.
